Clinical Trial Update: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of CFI-400945 and Durvalumab in advanced triple-negative breast cancer; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CFI-400945 (CFI-400945)
• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-09